GMAB
Genmab A/S
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+77/100
Last price
37.39
▼ 1.09 (2.83%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
38.79
Prev close
38.48
Day high
39.15
Day low
37.07
Volume
6.60M
Market cap
$23.24B
P/E (TTM)
30.48
52W range
23.62 – 40.17
Day trading desk
Gap from prior close
+0.80%
Prior close 38.48
VWAP
37.79
-1.07% from price
Relative volume
4.78×
Unusually busy
Session range
19.37%
37.07 – 44.25
Position in range
4%
Near session low
ATR (14D)
1.25
3.35% of price
Prior day high
40.17
PDH
Prior day low
35.02
PDL
Bid / ask spread
—
Quote not published
Session volume
13.00M
Avg 2.72M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+6.27%
+4.3%
1M
+12.50%
+11.3%
3M
+27.96%
+23.4%
6M
+36.71%
+18.5%
YTD
+22.73%
+8.5%
1Y
+12.63%
-3.8%
3Y
+7.17%
-75.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GMAB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$23.24B
Enterprise value$26.33B
Revenue (TTM)$4.13B
Gross profit$3.84B
EBITDA$1.38B
Net income$788.00M
EPS (TTM)$1.24
Free cash flow$870.63M
Total cash$1.51B
Total debt$5.27B
Book value / share$9.98
Shares outstanding614.90M
Float589.61M
Short % of float0.81%
Dividend yield0.00%
Beta (5Y)0.65
Valuation & profitability ratios
Trailing P/E30.48
Forward P/E24.71
PEG ratio4.87
Price / sales—
Price / book3.79
EV / revenue6.37
EV / EBITDA19.12
Gross margin93.03%
Operating margin35.24%
Profit margin19.07%
Return on equity14.00%
Return on assets8.79%
Debt / equity88.52
Current ratio2.46
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $3.72B | $3.12B | $2.39B | $2.09B | — | +19.2% |
| Operating revenue | $3.67B | $2.98B | $2.27B | $1.97B | — | +23.2% |
| Cost of revenue | $238.00M | $143.00M | $33.00M | $0 | — | +66.4% |
| Gross profit | $3.48B | $2.98B | $2.36B | $2.09B | — | +16.9% |
| Research & development | $1.61B | $1.41B | $1.11B | $800.53M | — | +13.6% |
| Selling, general & admin | $626.00M | $549.00M | $478.00M | $385.15M | — | +14.0% |
| Total operating expense | $2.23B | $1.96B | $1.58B | $1.19B | — | +13.7% |
| Operating income | $1.25B | $1.01B | $772.00M | $902.00M | — | +23.2% |
| Net interest income | $77.00M | $126.00M | $132.00M | $41.02M | — | -38.9% |
| Pre-tax income | $1.20B | $1.33B | $817.00M | $999.58M | — | -9.2% |
| Tax provision | $241.00M | $193.00M | $186.00M | $214.89M | — | +24.9% |
| Net income | — | $1.13B | $631.00M | $784.70M | $450.16M | — |
| Net income to common | $963.00M | $1.13B | $631.00M | $784.70M | — | -15.0% |
| Basic EPS | 1.55 | 1.71 | 0.97 | 1.22 | — | -9.1% |
| Diluted EPS | 1.54 | 1.69 | 0.96 | 1.20 | — | -9.2% |
| EBIT | $1.26B | $1.34B | $827.00M | $1.01B | — | -5.9% |
| EBITDA | $1.34B | $1.40B | $870.00M | $1.06B | — | -4.8% |
| Basic shares | 621.51M | 641.87M | 653.10M | 657.83M | — | -3.2% |
| Diluted shares | 626.92M | 646.33M | 658.98M | 660.10M | — | -3.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.72B | $1.38B | $2.20B | $1.42B | +24.3% |
| Cash & short-term investments | $1.72B | $2.95B | $4.17B | $3.21B | -41.9% |
| Accounts receivable | $1.11B | $923.00M | $733.00M | $822.12M | +20.5% |
| Inventory | $18.00M | $9.00M | $8.00M | $0 | +100.0% |
| Total current assets | $2.88B | $3.90B | $4.91B | $4.06B | -26.0% |
| Property, plant & equipment | $280.00M | $265.00M | $244.00M | $190.27M | +5.7% |
| Goodwill & intangibles | $9.48B | $2.08B | $15.00M | $21.01M | +355.0% |
| Total assets | $12.87B | $6.41B | $5.23B | $4.33B | +100.7% |
| Total current liabilities | $1.43B | $744.00M | $368.00M | $262.38M | +91.8% |
| Current debt | $273.00M | — | — | — | — |
| Long-term debt | $5.00B | — | — | — | — |
| Total debt | $5.43B | $144.00M | $114.00M | $85.93M | +3,668.1% |
| Total liabilities | $7.03B | $1.28B | $545.00M | $408.32M | +450.2% |
| Retained earnings | $4.10B | $3.39B | $2.74B | $2.13B | +20.8% |
| Shareholder equity | $5.85B | $5.14B | $4.69B | $3.93B | +13.8% |
| Working capital | $1.46B | $3.16B | $4.54B | $3.80B | -53.8% |
| Net tangible assets | -$3.63B | $3.05B | $4.67B | $3.91B | -218.9% |
| Shares issued | 64.24M | 66.19M | 66.07M | 65.96M | -2.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.20B | $1.33B | $817.00M | $999.58M | -9.2% |
| Depreciation & amortisation | $71.00M | $60.00M | $43.00M | $52.10M | +18.3% |
| Stock-based compensation | $128.00M | $105.00M | $85.00M | $63.18M | +21.9% |
| Change in working capital | $225.00M | -$109.00M | $198.00M | -$264.83M | +306.4% |
| Operating cash flow | $1.19B | $1.13B | $1.07B | $563.05M | +5.3% |
| Capital expenditure | -$55.00M | -$44.00M | -$54.00M | -$45.63M | -25.0% |
| Investing cash flow | -$5.64B | -$1.45B | -$185.00M | -$397.39M | -290.0% |
| Share buybacks | -$430.00M | -$560.00M | -$81.00M | -$130.69M | +23.2% |
| Financing cash flow | $4.79B | -$566.00M | -$89.00M | -$113.56M | +946.1% |
| Free cash flow | $1.13B | $1.08B | $1.02B | $517.42M | +4.5% |
| End cash position | $1.72B | $1.38B | $2.20B | $1.42B | +24.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.16B | $896.00M | $1.06B | $1.02B | $925.00M | — | +28.9% |
| Operating revenue | $1.16B | $888.00M | $1.00B | $1.02B | $925.00M | — | +30.1% |
| Cost of revenue | $84.00M | $65.00M | $81.00M | $58.00M | $57.00M | — | +29.2% |
| Gross profit | $1.07B | $831.00M | $977.00M | $964.00M | $868.00M | — | +28.9% |
| Research & development | $459.00M | $440.00M | $526.00M | $357.00M | $364.00M | — | +4.3% |
| Selling, general & admin | $205.00M | $166.00M | $208.00M | $148.00M | $144.00M | — | +23.5% |
| Total operating expense | $664.00M | $606.00M | $734.00M | $505.00M | $508.00M | — | +9.6% |
| Operating income | $407.00M | $225.00M | $243.00M | $459.00M | $360.00M | — | +80.9% |
| Net interest income | -$74.00M | -$98.00M | $4.00M | $29.00M | $16.00M | — | +24.5% |
| Pre-tax income | $295.00M | $74.00M | $55.00M | $482.00M | $423.00M | — | +298.6% |
| Tax provision | -$8.00M | $21.00M | $24.00M | $81.00M | $87.00M | — | -138.1% |
| Net income | $303.00M | $53.00M | $31.00M | $401.00M | $336.00M | — | +471.7% |
| Net income to common | $303.00M | $53.00M | $31.00M | $401.00M | $336.00M | — | +471.7% |
| Basic EPS | 0.49 | 0.08 | — | 0.65 | 0.54 | 0.31 | +488.1% |
| Diluted EPS | 0.49 | 0.08 | — | 0.65 | 0.54 | 0.31 | +491.6% |
| EBIT | $405.00M | $186.00M | $99.00M | $485.00M | $432.00M | — | +117.7% |
| EBITDA | $431.00M | $215.00M | $120.00M | $503.00M | $448.00M | — | +100.5% |
| Basic shares | 613.36M | 630.95M | — | 615.98M | 617.65M | 637.25M | -2.8% |
| Diluted shares | 617.11M | 638.55M | — | 620.74M | 619.93M | 639.34M | -3.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.50B | $1.52B | $1.72B | $1.76B | $1.30B | -1.2% |
| Cash & short-term investments | $1.50B | $1.52B | $1.72B | $3.41B | $2.90B | -1.2% |
| Accounts receivable | $1.21B | $968.00M | $1.11B | $1.05B | $998.00M | +25.2% |
| Inventory | $18.00M | $21.00M | $18.00M | $14.00M | $13.00M | -14.3% |
| Total current assets | $2.80B | $2.57B | $2.88B | $4.47B | $3.91B | +8.9% |
| Property, plant & equipment | $254.00M | $265.00M | $280.00M | $266.00M | $277.00M | -4.2% |
| Goodwill & intangibles | $9.23B | $9.30B | $9.48B | $2.10B | $2.11B | -0.8% |
| Total assets | $12.52B | $12.38B | $12.87B | $7.02B | $6.46B | +1.1% |
| Total current liabilities | $1.14B | $1.18B | $1.43B | $741.00M | $629.00M | -3.2% |
| Current debt | $294.00M | $275.00M | $273.00M | — | — | +6.9% |
| Long-term debt | $4.84B | $4.93B | $5.00B | — | — | -1.9% |
| Total debt | $5.27B | $5.35B | $5.43B | $142.00M | $148.00M | -1.5% |
| Total liabilities | $6.56B | $6.69B | $7.03B | $1.27B | $1.16B | -2.0% |
| Retained earnings | $4.42B | $4.09B | $4.10B | $4.03B | $3.60B | +8.1% |
| Shareholder equity | $5.96B | $5.68B | $5.85B | $5.75B | $5.30B | +4.8% |
| Working capital | $1.66B | $1.40B | $1.46B | $3.73B | $3.28B | +19.1% |
| Net tangible assets | -$3.27B | -$3.62B | -$3.63B | $3.65B | $3.19B | +9.7% |
| Shares issued | 62.40M | 64.25M | 64.24M | 64.21M | 64.15M | -2.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $295.00M | $74.00M | $55.00M | $482.00M | $423.00M | +298.6% |
| Depreciation & amortisation | $26.00M | $29.00M | $21.00M | $18.00M | $16.00M | -10.3% |
| Stock-based compensation | $37.00M | $49.00M | $36.00M | $34.00M | $33.00M | -24.5% |
| Change in working capital | -$267.00M | -$113.00M | $253.00M | $2.00M | -$105.00M | -136.3% |
| Operating cash flow | $51.00M | $3.00M | $301.00M | $536.00M | $62.00M | +1,600.0% |
| Capital expenditure | -$3.00M | -$5.00M | -$13.00M | -$2.00M | -$10.00M | +40.0% |
| Investing cash flow | $2.00M | -$9.00M | -$5.57B | -$54.00M | $26.00M | +122.2% |
| Share buybacks | $0 | -$96.00M | $0 | -$24.00M | -$406.00M | +100.0% |
| Financing cash flow | -$75.00M | -$177.00M | $5.23B | -$21.00M | -$406.00M | +57.6% |
| Free cash flow | $48.00M | -$2.00M | $288.00M | $534.00M | $52.00M | +2,500.0% |
| End cash position | $1.50B | $1.52B | $1.72B | $1.76B | $1.30B | -1.2% |
Options analytics
Put / call volume
0.11
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
17.50
-53.7% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
1.13K
Contracts, this expiry
Put volume
121
Contracts, this expiry
Heaviest call OI
17.50
0 contracts
Heaviest put OI
30.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.35 | 0.49 | +41.8% |
| Mar 2026 | 0.19 | 0.13 | -29.7% |
| Dec 2025 | 0.37 | 0.21 | -44.6% |
| Sep 2025 | 0.45 | 0.65 | +42.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.33 | 6 | $7.90B | +19.5% |
| Next quarter | 0.27 | 6 | $8.33B | +24.7% |
| Current year | 1.18 | 1 | $29.47B | +25.4% |
| Next year | 1.53 | 1 | $34.23B | +16.1% |
Analyst targets & ownership
Mean target$42.40
High target$54.00
Low target$33.50
Implied upside13.40%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy1 / 10
Hold1
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions17.03%
Institutions holding379
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
35.71
+4.71% from price
SMA 20
34.76
+8.74% from price
SMA 50
33.04
+14.40% from price
SMA 100
29.95
+24.86% from price
SMA 200
29.69
+27.31% from price
EMA 12
35.76
+4.57% from price
EMA 26
34.69
+7.78% from price
EMA 50
33.23
+12.51% from price
RSI (14)
69.0
Neutral
MACD (12,26,9)
1.06
Hist 0.20
ATR (14)
1.25
3.31% of price
Realised vol 30D
39.9%
Annualised
Bollinger upper
37.76
20, 2σ
Bollinger lower
31.76
20, 2σ
50 / 200 cross
Golden
33.04 vs 29.69
Trend bias
Above 200
+27.31%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.78
Less volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
39.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-32.5%
Peak to trough
Max drawdown 5Y
-61.8%
Peak to trough
ATR 14
1.25
3.31% of price
Beta (reported)
0.65
5Y monthly, from filing
Short interest
Shares short
4.92M
Prior 7.60M
Change vs prior
-35.2%
Shorts covering
% of float
0.81%
Normal
% of shares out
0.80%
Against total outstanding
Days to cover
2.2
Liquid
Float
589.61M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 22, 26 | TD Cowen | UPGRADE | Hold | Buy |
| Jul 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 23, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 30, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 27, 26 | Wolfe Research | INITIATED | — | Outperform |
| Mar 2, 26 | Wells Fargo | INITIATED | — | Overweight |
| Feb 23, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Feb 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split5:1
Split dateMay 1, 2018
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-10-05
Corporate Changes & Voting Matters
6-K · 2026-10-02
Corporate Changes & Voting Matters
6-K · 2026-09-29
Corporate Changes & Voting Matters
6-K · 2026-09-24
Corporate Changes & Voting Matters
6-K · 2026-09-09
Corporate Changes & Voting Matters
6-K · 2026-09-08
Corporate Changes & Voting Matters
6-K · 2026-08-12
Corporate Changes & Voting Matters
6-K · 2026-08-11
Headlines
AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%
GuruFocus.com · 9h ago
European shares rise as retreating bond yields and oil prices boost risk appetite
Reuters · 12h ago
AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says
MT Newswires · 12h ago
Genmab’s Lymphoma Bet Delivers a 51% Knockout
Moby · 12h ago
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
BioPharma Dive · 13h ago
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
Zacks · 14h ago
Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug
The Wall Street Journal · 20h ago
Genmab jumps as its lymphoma drug combo with AbbVie cuts progression, death risk
Investing.com · 21h ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.